IP Library Granted Patent US 10,098,952
Granted Patent B2
US 10,098,952 · App. 14/762,971 · Granted Oct 16, 2018

Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Inventors: Elsa Borghi (Saint-Rémy-lès-Chevreuse, FR); Laurent Levy (Paris, FR); Agnès Pottier (Paris, FR)
Assignee: NANOBIOTIX
A61K41/0038A61K9/14B82Y5/00A61N2005/1087A61N2005/1089A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,952
App. No.
14/762,971
Granted
Oct 16, 2018
Kind
B2
Abstract

The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Claims (11)

1. A method for inducing in a human subject suffering from a cancer (i) destruction of more than 70% of cancer cells in a tumor volume or (ii) reduction of more than 20% of tumor size, comprising administering to the human subject suffering from the cancer and having a tumor a composition comprising inorganic nanoparticles having a volume that is between 2% and of and 15% of the tumor volume and an electron density at least 5 times the electron density of a corresponding volume 1 (Vw1) of water, and exposing the tumor of the subject to ionizing radiation, thereby inducing in the human subject having the tumor (i) the destruction of more than 70% of cancer cells in the tumor or (ii) reduction of more than a 20% of tumor size, when the tumor is exposed to ionizing radiation and the inorganic nanoparticles provide more than 7×10 22 electrons to the tumor.

2. The method according to claim 1 , wherein the volume of the composition (Vc) comprising inorganic nanoparticles has an electron density of at least 3% of the electron density of a corresponding volume 2 (Vw2) of water.

3. The method according to claim 1 , wherein the inorganic nanoparticles comprise an inorganic material that has a theoretical (bulk) density of at least 7 and an effective atomic number (Z eff ) of at least 25.

4. The method according to claim 3 , wherein the inorganic material is selected from an oxide, a metal, a sulfide or any mixture thereof.

5. The method according to claim 1 , wherein the largest dimension of a nanoparticle is between about 5 nm and about 250 nm.

6. The method according to claim 1 , wherein the composition is a pharmaceutical composition in a liquid or gel form.

7. The method according to claim 1 , wherein the tumor is a malignant solid tumor or lymphatic cancer.

8. The method according to claim 1 , wherein said ionizing radiation is selected from X-rays, ion beams, electron beams, gamma-rays, and a radioactive isotope.

9. The method according to claim 1 , wherein said composition has a volume that is between 2% and 10% of the tumor volume.

10. The method according to claim 1 , wherein said composition has a volume that is 2.5% of the tumor volume.

11. The method according to claim 1 , wherein said composition is administered intra-tumorally.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 036910 FRAME 0093. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Nov 8, 2021
From: BORGHI, ELSA; LEVY, LAURENT; POTTIER, AGNÈS
To: NANOBIOTIX S.A.
Reel/Frame 058044/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2015
From: BORGHI, ELSA; LEVY, LAURENT; POTTIER, AGNES
To: NANOBIOTIX
Reel/Frame 036910/0093 →
Priority Claims (1)
EP 13305087 · Jan 25, 2013 · regional
Continuity (2)
Provisional Application 61756533 · Jan 25, 2013
Related Publication 20150374818A1 · Dec 31, 2015
Cited By (3)
US 50,811 US 12,569,700 US 12,653,890